azacitidine / Generic mfg. - LARVOL DELTA

Prognostic impact of geriatric assessment in acute myeloid leukemia patients treated with azacitidine-venetoclax (SIOG 2025) - "In older patients treated with AZA+VEN, G8 score impacted OS independently of molecular features.."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • RELN • TP53

Use of 7+3 Chemotherapy After Azacitidine/Venetoclax Induction in AML: A Small Retrospective Cohort from Real-World Practice (ASHP 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Acute Myelogenous Leukemia

Prognostic impact of geriatric assessment in acute myeloid leukemia patients treated with azacitidine-venetoclax (SIOG 2025) - "In older patients treated with AZA+VEN, G8 score impacted OS independently of molecular features.."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • RELN • TP53

Outcomes of Venetoclax-Azacitidine as a Bridge to Transplant in Relapsed/Refractory AML: A Real-World UK Cohort (ASHP 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Transplantation

Prognostic impact of geriatric assessment in acute myeloid leukemia patients treated with azacitidine-venetoclax (SIOG 2025) - "In older patients treated with AZA+VEN, G8 score impacted OS independently of molecular features.."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • RELN • TP53

Prognostic impact of geriatric assessment in acute myeloid leukemia patients treated with azacitidine-venetoclax (SIOG 2025) - "In older patients treated with AZA+VEN, G8 score impacted OS independently of molecular features.."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • RELN • TP53

Redox-dependent protein S-glutathionylation governs azacitidine sensitivity and resistance in AML. (PubMed, Redox Biol) - "Importantly, AZA failed to induce oxidation of proteins in these pathways in resistant cells and patient-derived AML samples. Pharmacological inhibition of glutathione synthesis restored protein S-glutathionylation and resensitized resistant AML cells to AZA."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Phase 1/2, multi-center, open-label clinical study to evaluate the safety, pharmacokinetics, and efficacy of Zefamenib combined with chemotherapy or targeted Agents in patients with Acute Myeloid Leukemia (ASH 2025) - P1/2 | "Menin inhibitor revumenib combined with venetoclax and azacitidine have shown complete remission (CR) rate of 88.4% in newly diagnosed AML patients harboring these aberrations...Cohort A and D will enroll untreated AML patients, who will receive zefamenib combined with standard 7+3 chemotherapy for induction and zefamenib combined with high dose cytarabine for consolidation...This study will be the first to clarify the feasibility of zefamenib with intensive chemotherapy or targeted agents in the frontline treatment of AML patients or the efficacy and safety of zefamenib with targeted agents in R/R AML patients harboring NPM1 mutation or KMT2A/NUP98 rearrangements. Results of this study will provide ideas and evidence to improve the prognosis of Chinese AML patients with these genetic aberrations."

Clinical • P1/2 data • PK/PD data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • KMT2A • MEIS1 • NPM1 • NUP98

PyramIDH: A phase 3 study of ivosidenib monotherapy or azacitidine monotherapy in patients with mutant isocitrate dehydrogenase 1 myelodysplastic syndromes who have not received prior hypomethylating agent therapy (ASH 2025) - P1, P3 | "As of July 15, 2025, 34 sites are open for enrollment in 9 countries. In total, 19 patients have been prescreened, 4 have been screened, and 3 patients have been enrolled."

Clinical • Monotherapy • P3 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • IDH1

Comparing the efficacy and safety of the ABC-14 regimen (Azacitidine, Venetoclax, and Chidamide) with traditional "3+7" intensive induction regimen or AB-14 regimen (Venetoclax Combined with Azacitidine) in newly diagnosed AML: Study protocol for a prospective, multicenter, randomized, open-label clinical trial (ASH 2025) - P2 | "To provide a alternative treatment for induction therapy of newly diagnosed AML indiscriminately. Trial registration ClinicalTrials.gov NCT06451861, Registered on 2024.06.11, https://clinicaltrials.gov/study/NCT06451861 Keywords Acute myeloid leukemia, unfit-AML, fit-AML, induction therapy, Protocol"

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • MCL1 • RUNX1 • TP53

Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study (ASH 2025) - "Previous data showed that the multi-drug combination regimen of IVO demonstrates good tolerability and efficacy. This study will be the first to clarify the feasibility of multi-drug regimens in the treatment of IDH1m AML patients in China, providing ideas and evidence to improve the prognosis of Chinese IDH1m AML patients."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • IDH1

Real-world outcomes associated with azacitidine and venetoclax in Myelodysplastic Syndromes (ASH 2025) - "Conclusion : Treatment with azacitidine and venetoclax in patients with higher-risk MDS may be helpful to achieve disease control quickly providing benefit in those intending to proceed to SCT. In our population, azacitidine and venetoclax did not provide long term disease control, especially in TP53-mutated disease."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Aplastic Anemia • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Septic Shock • Thrombocytopenia • TP53

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine (ASH 2025) - "Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after standard 7+3 induction (7 days of cytarabine plus 3 days of an anthracycline) is usually FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor [G-CSF], and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine)...Although the venetoclax–cytarabine (VEN-ARAC) or venetoclax–azacitidine (VEN-AZA) combination is approved as first-line therapy for unfit patients, it is generally not available in SUS... In this real-world study, VEN-based salvage therapy induced rapid and high CR rates after 7+3 or LDAC, with a favorable safety profile, and may serve as a less-toxic bridge to allo-HSCT."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Azole-adjusted venetoclax-based regimens in unfit AML patients: A real-world brazilian experience from a resource-limited setting (ASH 2025) - "After 2020, unfit patients were treated with Venetoclax-based regimens (n=54), either combined with Azacitidine 75 mg/m²/day SC for 7 days (AZA-VEN) or with low-dose Cytarabine 20 mg/m²/day SC for 10 days (LoDAC-VEN). All patients received, after ramp-up, azole-adjusted dosing of Venetoclax: 100 mg when combined with Voriconazole or 200 mg with Fluconazole... In this real-world study, Venetoclax-based regimens with azole-adjusted dosing showed better outcomes in unfit AML patients compared to LoDAC or BSC, reinforcing the applicability of such regimens in resource-limited settings. While overall survival in our cohort was lower than reported in pivotal trials, likely due to infectious complications and limited access to supportive care, response rates were comparable. These results support broader incorporation of this approach across diverse healthcare systems."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L) (ASH 2025) - "Background: Older patients with acute myeloid leukemia (AML), those with multiple comorbidities, and/or poor performance status are generally considered ineligible for intense chemotherapy and are often treated with combination therapy of hypomethylating agents (HMAs) (azacitidine or decitabine) and venetoclax (VEN) as the standard of care. This real-world study showed that 1L combination of HMA+VEN was effective in managing AML patients that are ineligible for intense chemotherapy. However, treatment modifications due to cytopenia were common. The longer observed rwOS is likely reflective of a younger, high-functioning patient population with favorable ELN risk profile, subsequent therapies used (including stem cell transplant), and/or improvements in dose optimization in clinical practice."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia

Utilization patterns of venetoclax-based regimens for AML in a community based setting & representative populational analyses (ASH 2025) - "In first line setting, 22 patients (52.3%) received Venetoclax with azacitidine, 17 patients 40.1% received decitabine, 2 patients (4.8%) with cladribine and cytarabine, and 2 patients (4.8%) received Venetoclax alone...6 patients (40%) received azacitidine with venetcloax, 6 patients (40%) received decitabine, 1 patient (6.7%) received cytarabine, 1 patient (6.7%) received enasidenib, and one patient (6.7%) received nelarabine, cyclophosphamide, and cytarabine... The median age at diagnosis was 64 years (range 21-86). 47% patients were female gender. 24.5% of patients were Black or African-American, 71.4% were White, 1% were Asian, and 3.1% were more than one race."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Hepatology • Liver Failure • Neutropenia • Renal Disease • CEBPA • DDX41 • NPM1 • TP53

Validation of the ELN2024 less-intensive prognostic stratification in newly diagnosed AML patients receiving venetoclax-azacitidine: A real-world study from China (ASH 2025) - "In this real-world Chinese cohort, ELN 2024 Less-Intensive stratification clearly separated survival outcomes and outperformed ELN 2022 in VA-treated AML. MRD negativity remained a robust predictor of favorable RFS, and PTPN11 mutations were associated with early relapse. Larger multicenter studies are warranted."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • PTPN11

Administration of chemoterapy at home for "unfit" hematological patients: A safe and cost-effective way. (ASH 2025) - "Materials and During 2022 we provide identification of patients suffering from Myelodysplastic Syndrome, Multiple Myeloma, and Chronic Lymphatic Leukemia requiring chemotherapy and among these the number of patients defined as UNFIT.We activated two projects of home sub cutaneous or oral chemotherapy as follow: PROJECT N° 1:DOMICILIATION OF CHEMOTHERAPY PER ORAL WITH OBLIGATION OF AIFA CARD for patients affected by Multiple Myeloma and Chronic lymphocytic leukemia PROJECT N° 2: DOMICILIATION OF Sub Cutaneos CHEMOTHERAPY for patients affected by Multiple Myeloma in therapy with VELCADE; - Myelodysplastic syndrome in therapy with VIDAZA. The path for the future is set to effectively respond to the ever-increasing needs of patients due to social and demographic changes. The Hematology Department of the Ragusa Local Health Authority intends to continue in this direction, as being treated at home is very different, psychologically and emotionally, from being..."

Clinical • Cost effectiveness • HEOR • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome

Less is more: Improving outcomes in haemato-oncology with optimal antibiotic use for febrile neutropenia (ASH 2025) - "Management of FN: Rapid administration of piperacillin-tazobactam and amikacin (Piptaz/Ami) for fever (≥38°C) with neutropenia (≤0.5x10 9 /L or expected neutropenia) after taking BCs...Two patients had relapsed AML, 2 newly diagnosed AML (on Venetoclax/Azacytidine and one on palliative Hydroxycarbamide), and 1 post-haploidentical HSCT for lymphoma... Patient population: 49% had AML/MDS; 66% had active disease (presentation or relapse). Treatment modalities: intensive chemotherapy (37%) autologous (37%) or allogeneic HSCT (13%). Median age was 57 years (23-85)."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cerebral Hemorrhage • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Myelodysplastic Syndrome • Neutropenia • Pneumonia • Renal Disease

Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination (ASH 2025) - "Despite extensive genomic insights, conventional chemotherapies, specifically anthracyclines and cytarabine , have remained the cornerstone of treatment for the past four decades...In contrast, selective inhibitors of JAK-STAT (ruxolitinib) or FLT3 (gilteritinib or quizartinib) alone failed to demonstrate comparable synergy, highlighting the distinct polypharmacological profile of momelotinib in mediating the cytotoxic response...Notably, while the efficacy of gilteritinib-based regimens was restricted to FLT3-mutant AML, the momelotinib combination demonstrated activity across both FLT3 mutant and FLT3 wild-type contexts. Altogether these preclinical data support clinical evaluation of momelotinib in combination with venetoclax and azacitidine as a potential effective treatment in AML."

Combination therapy • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ACVR1 • FLT3 • IRAK1

Post-allogenic hematopoietic stem cell transplant ( Allo-HSCT), hypomethylating-agent maintenance improves survival without increasing GVHD (Graft versus host disease) in AML/MDS( Acute myeloid leukemia/Myelodysplastic syndrome): Updated systematic review and meta-analysis (ASH 2025) - "Hypomethylating agents (HMAs) such as azacitidine and decitabine are increasingly used as post-transplant maintenance, but the magnitude of benefit after the latest clinical reports is unclear. Importantly, HMA maintenance did not increase the risk of grade III–IV acute GVHD (RR = 0.86, 95% CI: 0.38–1.94) or chronic GVHD (RR = 0.94, 95% CI: 0.65–1.34) Conclusions This updated meta-analysis demonstrates that HMA maintenance after allo-HSCT confers clinically meaningful gains in overall and relapse-free survival, driven by both reduced relapse and lower non-relapse mortality, without increasing severe acute or chronic GVHD. These data support integrating HMAs into post-transplant protocols for high-risk AML/MDS."

Retrospective data • Review • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia post allogeneic hematopoietic stem cell transplantation. (ASH 2025) - "Objective: To evaluate the efficacy and safety of venetoclax (VEN), cytarabine, and azacitidine (AZA) combination therapy in relapsed acute myeloid leukemia (AML) patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The VEN-cytarabine-AZA triple-drug regimen is an effective option for relapsed AML after allo-HSCT. However, prolonged neutropenia and thrombocytopenia necessitate vigilant monitoring for severe infections."

Combination therapy • Retrospective data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplantation • CBFB • KMT2A • NUP98

Frequency of and finding risk factors for thromboembolism and major bleeding in patients with myelodysplastic syndrome undergoing allogeneic transplantation (ASH 2025) - "Four were on decitabine, 1 was on lenalidomide, and 1 was on azacitidine. Rates of TEE and bleed in MDS patients undergoing allo-SCT were similar and common at 26% and 22%, respectively. Bleeding, but not TEE, seemed to impact survival in line with one other report (Gergi et al. Blood 2024)."

Clinical • Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Thrombosis • Transplantation

Azacitidine (AZA) and donor lymphocyte infusion (DLI) is a viable salvage approach for chimerism-only relapse following allogeneic blood or marrow transplantation (BMT) (ASH 2025) - "All except one received reduced-intensity conditioning, and all received post-transplant cyclophosphamide as GVHD prophylaxis backbone. Our data support AZA-DLI as a feasible strategy for managing post-BMT relapse even in a predominant haplo-BMT population, or when used many years after BMT. Pre-emptive intervention with DLI in a setting of mixed chimerism is associated with superior outcomes, while monitoring for GVHD is warranted."

Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Transplantation

Myelodysplastic syndrome in Tanzania; The current status of management (ASH 2025) - "Erythropoiesis-stimulating agents, lenalidomide, and cyclosporine were administered to 4.9%, 6.6%, and 8.2% of patients, respectively. Azacitidine, a hypomethylating agent, was offered to only 1.6% of patients...Supportive care remains the mainstay of management, with limited use of disease-specific therapies. This emphasizes the pressing need to strengthen diagnostic infrastructure and make treatment options available to align with global standards and improve the outcomes of MDS patients in low-resource settings."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome